Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555796 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
A Phase 1 study of Prostate Cancer and High-risk Biochemical Recurrence, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT06555796: Active Phase 1 study of Prostate Cancer and High-risk Biochemical Recurrence, sponsored by Amgen.
NCT06555796 is a Phase 1 study of Prostate Cancer and High-risk Biochemical Recurrence that is active but no longer recruiting, run by Amgen. The registered enrollment target is 50 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06555796, a Phase 1 study of Prostate Cancer and High-risk Biochemical Recurrence, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Primary Outcome
Events categorized as adverse events (AEs) starting on or after first dose of investigational product (xaluritamig) as determined by the flag indicating if the AE started prior to the first dose on the Events Electronic Case Report Form (eCRF) and including 30 days after the last dose of investigational product (xaluritamig) or end of study date, whichever is earlier.
Conditions Studied
Interventions
- DRUG Xaluritamig
Study Locations (11)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Levine Cancer Institute - Charlotte
Victoria
- Cabrini Hospital - Malvern
- Peter MacCallum Cancer Centre - Melbourne
Minnesota
- University of Minnesota Medical Center Fairview - Minneapolis
New York
- Memorial Sloan Kettering Cancer Center - New York
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- Thomas Jefferson University - Philadelphia
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2028-12-02 |
| Phase | Phase 1 |
What the registry record for NCT06555796 still lists
NCT06555796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Xaluritamig is the first listed.
NCT06555796 lists 11 locations in 9 states (North Carolina, Victoria, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06555796 about?
NCT06555796 is a clinical study titled "Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer". The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
What is the current status of trial NCT06555796?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-09-23. Estimated completion is 2028-12-02.
What conditions does trial NCT06555796 study?
This clinical trial studies the following conditions: Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer.
What interventions are being tested in trial NCT06555796?
The interventions under investigation include: Xaluritamig (DRUG).
Who is sponsoring clinical trial NCT06555796?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06555796 being conducted?
This trial has 11 study locations across Minnesota, New York, North Carolina, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06555796's enrollment target sits among peer trials
50 469th of 735 higher than 247 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI